IMPACT OF LONG-TERM TERAFLEX THERAPY ON SYMPTOMS AND QUALITY OF LIFE IN PATIENTSWITH EARLY STAGES OF GONARTHROSIS
https://doi.org/10.14412/1996-7012-2010-602
Abstract
Aim: to evaluate the impact of long-term Teraflex therapy on symptoms and quality of life in patients with early stages of gonarthrosis (GA) during a 3-year follow-up.
Subjects and methods. Two hundred and forty-four outpatients were examined. A study group included 104 patients who were given Teraflex from the moment of their inclusion into the study. One hundred and forty patients treated with diclofenac formed a control group. The time course of changes in clinical parameters (the Lequesne index, WOMAC index, and walking and rest visual analog scale (VAS) pain scores) and quality of life were estimated in patients in long Teraflex-treated and control patients.
Long-term Teraflex therapy showed a positive effect on the symptoms of the disease. There were positive changes in all clinical parameters just
months after daily use of the drug. The significance of the difference between VAS pain scores, the Lequesne index, WOMAC index, and baseline values remained following 1, 2, and 3 years of the follow-up. That between the baseline value and all the clinical parameters remained only for VAS pain scores in the control group just after 2 years of therapy. Three years following therapy, the values of all clinical parameters became close to the baseline values. Long-term therapy with repeated courses of Teraflex had a positive impact on the quality of life indices of all SF-36 scales. The most significant increase in the indices versus the baseline values was noted at 1- and 2-year follow-up and for a number of parameters at 3-year follow-up.
Conclusion. Long-term Teraflex therapy used in early stages of GA was effective against the symptoms of the disease and improved the quality of life in the patients.
Subjects and methods. Two hundred and forty-four outpatients were examined. A study group included 104 patients who were given Teraflex from the moment of their inclusion into the study. One hundred and forty patients treated with diclofenac formed a control group. The time course of changes in clinical parameters (the Lequesne index, WOMAC index, and walking and rest visual analog scale (VAS) pain scores) and quality of life were estimated in patients in long Teraflex-treated and control patients.
Long-term Teraflex therapy showed a positive effect on the symptoms of the disease. There were positive changes in all clinical parameters just
months after daily use of the drug. The significance of the difference between VAS pain scores, the Lequesne index, WOMAC index, and baseline values remained following 1, 2, and 3 years of the follow-up. That between the baseline value and all the clinical parameters remained only for VAS pain scores in the control group just after 2 years of therapy. Three years following therapy, the values of all clinical parameters became close to the baseline values. Long-term therapy with repeated courses of Teraflex had a positive impact on the quality of life indices of all SF-36 scales. The most significant increase in the indices versus the baseline values was noted at 1- and 2-year follow-up and for a number of parameters at 3-year follow-up.
Conclusion. Long-term Teraflex therapy used in early stages of GA was effective against the symptoms of the disease and improved the quality of life in the patients.
References
1. <div><p>Амирджанова В.Н., Койлубаева Г.М. Методология оценки качества жизни в практике ревматолога. Науч.-практич. ревматол. 2003; 2: 72-6.</p><p>Базоркина Д.И., Эрдес Ш. Социальная значимость ревматических заболеваний. Науч.-практич. ревматол. 2005; 6: 79-85.</p><p>Насонова В.А. Проблема остеоартроза в начале XXI века. Consilium medicum 2000; 2(6): 61-4.</p><p>Сизова Л.В. Оценка качества жизни в современной медицине. Науч.-практич. ревматол. 2003; 2: 38-46.</p><p>Алексеева Л.И. Современные подходы к лечению остеоартроза. РМЖ 2003; 4: 85-8.</p><p>Цурко В.В. Остеоартроз: гериартрическая проблема. РМЖ 2005; 13(24): 1627-31.</p><p>Алексеева Л.И., Чичасова Н.В., Беневоленская Л.И. и др. Комбинированный препарат «Артра» при лечении остеоартроза. Тер. арх. 2005; 11: 69-75.</p><p>Алексеева Л.И. Терапия остеоартроза с позиций доказательной медицины. Consilium medicum, экстравыпуск 2007; 8: 14.</p><p>Насонова В.А. Фармакотерапия остеоартроза. Леч. врач. 2004; 7: 22-4.</p><p>Верткин А.Л., Талибов О.Б. Лечение остеоартроза: роль хондропротекторов. Леч. врач. 2000; 9: 40-3.</p><p>McAlindon T., LaValley M. Glucosamin and chondroitin for treatment of osteoarthritis: a systematic quality assessment and metaanalysis. JAMA 2000; 283: 1469-75.</p><p>Altman R., Asch E., Bloch D. et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of the arthritis of the knee. Arthr Rheum 1986; 29: 1039-49.</p><p>Kellgren J.H., Lawrence J.S. Radiographic assessment of osteoarthritis. Ann Rheum Dis 1957; 16: 494-501.</p><p>Lequesne M., Samson M., Gerard P. et al. Pain-function indices for the follow-up of osteoarthritis of the hip and the knee. Rev Rheum Mal Osteoartic 1990; 57(9, pt2): 32-6.</p><p>Bellamy N., Buchanan W.W., Goldsmith C.H. et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1998; 15: 1833-40.</p></div><br />
Review
For citations:
Svetlova MS. IMPACT OF LONG-TERM TERAFLEX THERAPY ON SYMPTOMS AND QUALITY OF LIFE IN PATIENTSWITH EARLY STAGES OF GONARTHROSIS. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2010;4(2):47-53. (In Russ.) https://doi.org/10.14412/1996-7012-2010-602
Views:
1734
Email this article 